Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Ptc Therapeutics (PTCT) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Ptc Therapeutics' Gains from Sales and Divestitures rose 2999.34% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 2999.34%. This contributed to the annual value of $963543.0 for FY2024, which is 467.74% up from last year.
  • Ptc Therapeutics' Gains from Sales and Divestitures amounted to $1.2 million in Q3 2025, which was up 2999.34% from $1.1 million recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Gains from Sales and Divestitures high stood at $1.2 million for Q3 2025, and its period low was $298982.0 during Q1 2021.
  • In the last 5 years, Ptc Therapeutics' Gains from Sales and Divestitures had a median value of $751448.0 in 2023 and averaged $703866.5.
  • As far as peak fluctuations go, Ptc Therapeutics' Gains from Sales and Divestitures surged by 8232.86% in 2023, and later soared by 467.74% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $335114.0 in 2021, then surged by 50.65% to $504851.0 in 2022, then surged by 82.33% to $920488.0 in 2023, then rose by 4.68% to $963543.0 in 2024, then increased by 24.71% to $1.2 million in 2025.
  • Its Gains from Sales and Divestitures stands at $1.2 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.